- Home
- DVAX vs BAK Comparison
DVAX vs BAK Comparison
Compare DVAX & BAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DVAX
- BAK
- Stock Information
- Founded
- DVAX 1996
- BAK 1972
- Country
- DVAX United States
- BAK Brazil
- Employees
- DVAX N/A
- BAK N/A
- Industry
- DVAX Biotechnology: Pharmaceutical Preparations
- BAK Major Chemicals
- Sector
- DVAX Health Care
- BAK Industrials
- Exchange
- DVAX Nasdaq
- BAK Nasdaq
- Market Cap
- DVAX 1.3B
- BAK 1.3B
- IPO Year
- DVAX 2004
- BAK N/A
- Fundamental
- Price
- DVAX $9.70
- BAK $3.40
- Analyst Decision
- DVAX Buy
- BAK Buy
- Analyst Count
- DVAX 4
- BAK 2
- Target Price
- DVAX $26.50
- BAK $7.50
- AVG Volume (30 Days)
- DVAX 1.9M
- BAK 756.0K
- Earning Date
- DVAX 11-06-2025
- BAK 11-05-2025
- Dividend Yield
- DVAX N/A
- BAK N/A
- EPS Growth
- DVAX N/A
- BAK N/A
- EPS
- DVAX N/A
- BAK N/A
- Revenue
- DVAX $316,268,000.00
- BAK $14,266,076,929.00
- Revenue This Year
- DVAX $23.23
- BAK $4.10
- Revenue Next Year
- DVAX $16.57
- BAK $11.25
- P/E Ratio
- DVAX N/A
- BAK N/A
- Revenue Growth
- DVAX 26.66
- BAK 10.48
- 52 Week Low
- DVAX $9.20
- BAK $2.80
- 52 Week High
- DVAX $14.63
- BAK $7.71
- Technical
- Relative Strength Index (RSI)
- DVAX 41.54
- BAK 54.75
- Support Level
- DVAX $9.20
- BAK $3.28
- Resistance Level
- DVAX $9.94
- BAK $3.61
- Average True Range (ATR)
- DVAX 0.30
- BAK 0.12
- MACD
- DVAX -0.05
- BAK -0.00
- Stochastic Oscillator
- DVAX 40.65
- BAK 41.03
About DVAX Dynavax Technologies Corporation
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.
About BAK Braskem SA ADR
Braskem SA manufactures and sells chemicals, petrochemicals, fuels, and utilities. The company's geographical segments include Brazil; the United States and Europe and Mexico. It derives a majority of its revenue from Brazil. It produces olefins, such as ethylene, polymer and chemical-grade propylene, butadiene, and butene-1; fuels, such as automotive gasoline, liquefied petroleum gas, or LPG, ethyl tertiary-butyl ether, or ETBE, and methyl tertiary-butyl ether, or MTBE; intermediates, such as cumene and others.